Immunoglobulins: Global Market Outlook
Report Scope:
The scope of this study encompasses the current and forecast markets for normal and hyper immunoglobulins. The report segments markets based on product type and route of administration. The report surveys the competitive landscape, market dynamics and current and developing technologies. The report also analyzes the impact of COVID-19 on the market.
In terms of geographical regions, the report analyzes the market across North America, Europe, Asia-Pacific and the rest of the world (RoW). Key regions such as the U.S., Canada, Europe (U.K., Italy, France and Germany), Asia-Pacific (China, India and Japan) are highlighted in the discussion.
The report also analyzes key companies and their recent developments, such as product launches, business expansions and collaborations.
Report Includes:
The scope of this study encompasses the current and forecast markets for normal and hyper immunoglobulins. The report segments markets based on product type and route of administration. The report surveys the competitive landscape, market dynamics and current and developing technologies. The report also analyzes the impact of COVID-19 on the market.
In terms of geographical regions, the report analyzes the market across North America, Europe, Asia-Pacific and the rest of the world (RoW). Key regions such as the U.S., Canada, Europe (U.K., Italy, France and Germany), Asia-Pacific (China, India and Japan) are highlighted in the discussion.
The report also analyzes key companies and their recent developments, such as product launches, business expansions and collaborations.
Report Includes:
- A brief general outlook of the global market for immunoglobulins
- Analyses of the global market trends, with historic market revenue data (sales figures) for 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Estimation of the actual market size and revenue forecast for the global immunoglobulins market in USD million terms, and corresponding market share analysis by product type, route of administration, and region
- In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, current and future prospects in therapeutic treatments, and contributions to the overall market
- Identification of major stakeholders and analysis of the company competitive landscape based on their recent developments, financial performance, segmental revenues, and operational integration
- Company profiles of the market leading players
CHAPTER 1 INTRODUCTION
1.1 Market Snapshot
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OVERVIEW
3.1 Immunoglobulin G (IgG)
3.2 Immunoglobulin M (IgM)
3.3 Immunoglobulin A (IgA)
3.4 Immunoglobulin E (IgE)
3.5 Immunoglobulin D (IgD)
3.6 Immunoglobulins Mechanism of Action
3.7 Clinical Use of Immunoglobulins
3.7.1 Replacement Therapy with Immunoglobulins
3.7.2 Immunoglobulin Blood Tests
3.8 Market Dynamics
3.8.1 Market Drivers
3.8.2 Market Restraints
CHAPTER 4 EMERGING TECHNOLOGIES/ OPPORTUNITIES
4.1 Growing Investments in Plasma Fractionation Capacities
4.2 Increasing Research on New Formulations and Indications
4.3 Growing Opportunities in Emerging Nations
4.4 Adoption of Digital Initiatives
CHAPTER 5 MARKET BREAKDOWN BY TYPE, ROUTE OF ADMINISTRATION
5.1 Immunoglobulins Market, by Type
5.1.1 Normal Immune Globulins
5.1.2 Hyperimmune Globulins
5.1.3 Market Size and Forecast
5.2 Immunoglobulins Market, by Route of Administration
5.2.1 Intravenous (IV) Administration
5.2.2 Subcutaneous (SC) Administration
5.2.3 Others
5.2.4 Market Size and Forecast
5.3 Normal Immunoglobulins Market, by Application
5.3.1 Primary Immune Deficiency (PID)
5.3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.3.3 Secondary Immune Deficiency (SID)
5.3.4 Multifocal Motor Neuropathy (MMN)
5.3.5 Other Neurological Disorders
5.3.6 Other Applications
5.3.7 Market Size and Forecast
CHAPTER 6 MARKET BREAKDOWN BY REGION
6.1 Global Immunoglobulins Market Size, by Region
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Rest of the World
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Recent Key Developments
7.2 Product Launches
7.3 Mergers and Acquisitions
7.4 Business Expansions
7.5 Agreements and Collaborations
7.6 Clinical Trials Landscape
CHAPTER 8 COVID-19 IMPACT: IMMUNOGLOBULINS MARKET
8.1 COVID-19 Impact on the Immunoglobulins Market
8.1.1 Convalescent Plasma (CP) Therapy and Hyperimmune Globulins for COVID-19 Treatment
CHAPTER 9 COMPANY PROFILES
ADMA BIOLOGICS INC.
BAXTER INTERNATIONAL
BIO PRODUCTS LABORATORY LTD.
CHINA BIOLOGIC PRODUCTS INC.
CSL LTD.
GRIFOLS INTERNATIONAL S.A.
INNOVATIVE RESEARCH
INTAS PHARMACEUTICALS LTD.
KEDRION SPA
LFB S.A.
OCTAPHARMA AG
SANQUIN
TAKEDA PHARMACEUTICAL COMPANY LIMITED.
CHAPTER 10 PROJECT SCOPE AND METHODOLOGY
10.1 Scope of Report
10.2 Methodology
10.3 Analyst's Credentials
10.4 BCC Custom Research
10.5 Related BCC Research Reports
1.1 Market Snapshot
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OVERVIEW
3.1 Immunoglobulin G (IgG)
3.2 Immunoglobulin M (IgM)
3.3 Immunoglobulin A (IgA)
3.4 Immunoglobulin E (IgE)
3.5 Immunoglobulin D (IgD)
3.6 Immunoglobulins Mechanism of Action
3.7 Clinical Use of Immunoglobulins
3.7.1 Replacement Therapy with Immunoglobulins
3.7.2 Immunoglobulin Blood Tests
3.8 Market Dynamics
3.8.1 Market Drivers
3.8.2 Market Restraints
CHAPTER 4 EMERGING TECHNOLOGIES/ OPPORTUNITIES
4.1 Growing Investments in Plasma Fractionation Capacities
4.2 Increasing Research on New Formulations and Indications
4.3 Growing Opportunities in Emerging Nations
4.4 Adoption of Digital Initiatives
CHAPTER 5 MARKET BREAKDOWN BY TYPE, ROUTE OF ADMINISTRATION
5.1 Immunoglobulins Market, by Type
5.1.1 Normal Immune Globulins
5.1.2 Hyperimmune Globulins
5.1.3 Market Size and Forecast
5.2 Immunoglobulins Market, by Route of Administration
5.2.1 Intravenous (IV) Administration
5.2.2 Subcutaneous (SC) Administration
5.2.3 Others
5.2.4 Market Size and Forecast
5.3 Normal Immunoglobulins Market, by Application
5.3.1 Primary Immune Deficiency (PID)
5.3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.3.3 Secondary Immune Deficiency (SID)
5.3.4 Multifocal Motor Neuropathy (MMN)
5.3.5 Other Neurological Disorders
5.3.6 Other Applications
5.3.7 Market Size and Forecast
CHAPTER 6 MARKET BREAKDOWN BY REGION
6.1 Global Immunoglobulins Market Size, by Region
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Rest of the World
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Recent Key Developments
7.2 Product Launches
7.3 Mergers and Acquisitions
7.4 Business Expansions
7.5 Agreements and Collaborations
7.6 Clinical Trials Landscape
CHAPTER 8 COVID-19 IMPACT: IMMUNOGLOBULINS MARKET
8.1 COVID-19 Impact on the Immunoglobulins Market
8.1.1 Convalescent Plasma (CP) Therapy and Hyperimmune Globulins for COVID-19 Treatment
CHAPTER 9 COMPANY PROFILES
ADMA BIOLOGICS INC.
BAXTER INTERNATIONAL
BIO PRODUCTS LABORATORY LTD.
CHINA BIOLOGIC PRODUCTS INC.
CSL LTD.
GRIFOLS INTERNATIONAL S.A.
INNOVATIVE RESEARCH
INTAS PHARMACEUTICALS LTD.
KEDRION SPA
LFB S.A.
OCTAPHARMA AG
SANQUIN
TAKEDA PHARMACEUTICAL COMPANY LIMITED.
CHAPTER 10 PROJECT SCOPE AND METHODOLOGY
10.1 Scope of Report
10.2 Methodology
10.3 Analyst's Credentials
10.4 BCC Custom Research
10.5 Related BCC Research Reports
LIST OF TABLES
Summary Table: Global Market for Immunoglobulins, by Region, Through 2027
Table 1: Immunoglobulin Blood Tests to Diagnose Health Conditions
Table 2: Global Market for Immunoglobulins, by Type, Through 2027
Table 3: Comparison of Intravenous and Subcutaneous Immunoglobulins
Table 4: Global Market for Immunoglobulins, by Route of Administration, Through 2027
Table 5: Global Market for Normal Immunoglobulins, by Application, Through 2027
Table 6: Global Market for Immunoglobulins, by Region, Through 2027
Table 7: North American Market for Immunoglobulins, by Type, Through 2027
Table 8: North American Market for Immunoglobulins, by Route of Administration, Through 2027
Table 9: North American Market for Immunoglobulins, by Country, Through 2027
Table 10: European Market for Immunoglobulins, by Type, Through 2027
Table 11: European Market for Immunoglobulins, by Route of Administration, Through 2027
Table 12: European Market for Immunoglobulins, by Country, Through 2027
Table 13: Asia-Pacific Market for Immunoglobulins, by Type, Through 2027
Table 14: Asia-Pacific Market for Immunoglobulins, by Route of Administration, Through 2027
Table 15: Asia-Pacific Market for Immunoglobulins, by Country, Through 2027
Table 16: RoW Market for Immunoglobulins, by Type, Through 2027
Table 17: RoW Market for Immunoglobulins, by Route of Administration, Through 2027
Table 18: Product Launches, by Key Competitors, 2020-2022
Table 19: Mergers and Acquisitions of Key Competitors, 2020-2022
Table 20: Business Expansion Activities, by Key Competitors, 2020-2022
Table 21: Agreements and Collaborations Activities, by Key Competitors, 2020-2022
Table 22: Clinical Trial Activities of Key Competitors on Immunoglobulin Products
Table 23: ADMA Biologics Inc.: Product Portfolio
Table 24: ADMA Biologics Inc.: Developments and Strategies, 2022
Table 25: Bio Products Laboratory Ltd.: Product Portfolio
Table 26: Bio Products Laboratory Ltd.: Developments and Strategies, 2022
Table 27: China Biologic Products Inc.: Product Portfolio
Table 28: China Biologic Products Inc.: Developments and Strategies, 2022
Table 29: CSL Ltd.: Product Portfolio
Table 30: CSL Ltd.: Developments and Strategies, 2022
Table 31: Grifols International S.A.: Product Portfolio
Table 32: Grifols International S.A.: Developments and Strategies, 2022
Table 33: Kedrion SpA: Product Portfolio
Table 34: Kedrion SpA: Developments and Strategies, 2022
Table 35: LFB S.A.: Developments and Strategies, 2022
Table 36: Octapharma AG: Product Portfolio
Table 37: Octapharma AG: Developments and Strategies, 2022
Table 38: Takeda Pharmaceutical Company Limited: Product Portfolio
Table 39: Takeda Pharmaceutical Company Limited: Developments and Strategies, 2022
Summary Table: Global Market for Immunoglobulins, by Region, Through 2027
Table 1: Immunoglobulin Blood Tests to Diagnose Health Conditions
Table 2: Global Market for Immunoglobulins, by Type, Through 2027
Table 3: Comparison of Intravenous and Subcutaneous Immunoglobulins
Table 4: Global Market for Immunoglobulins, by Route of Administration, Through 2027
Table 5: Global Market for Normal Immunoglobulins, by Application, Through 2027
Table 6: Global Market for Immunoglobulins, by Region, Through 2027
Table 7: North American Market for Immunoglobulins, by Type, Through 2027
Table 8: North American Market for Immunoglobulins, by Route of Administration, Through 2027
Table 9: North American Market for Immunoglobulins, by Country, Through 2027
Table 10: European Market for Immunoglobulins, by Type, Through 2027
Table 11: European Market for Immunoglobulins, by Route of Administration, Through 2027
Table 12: European Market for Immunoglobulins, by Country, Through 2027
Table 13: Asia-Pacific Market for Immunoglobulins, by Type, Through 2027
Table 14: Asia-Pacific Market for Immunoglobulins, by Route of Administration, Through 2027
Table 15: Asia-Pacific Market for Immunoglobulins, by Country, Through 2027
Table 16: RoW Market for Immunoglobulins, by Type, Through 2027
Table 17: RoW Market for Immunoglobulins, by Route of Administration, Through 2027
Table 18: Product Launches, by Key Competitors, 2020-2022
Table 19: Mergers and Acquisitions of Key Competitors, 2020-2022
Table 20: Business Expansion Activities, by Key Competitors, 2020-2022
Table 21: Agreements and Collaborations Activities, by Key Competitors, 2020-2022
Table 22: Clinical Trial Activities of Key Competitors on Immunoglobulin Products
Table 23: ADMA Biologics Inc.: Product Portfolio
Table 24: ADMA Biologics Inc.: Developments and Strategies, 2022
Table 25: Bio Products Laboratory Ltd.: Product Portfolio
Table 26: Bio Products Laboratory Ltd.: Developments and Strategies, 2022
Table 27: China Biologic Products Inc.: Product Portfolio
Table 28: China Biologic Products Inc.: Developments and Strategies, 2022
Table 29: CSL Ltd.: Product Portfolio
Table 30: CSL Ltd.: Developments and Strategies, 2022
Table 31: Grifols International S.A.: Product Portfolio
Table 32: Grifols International S.A.: Developments and Strategies, 2022
Table 33: Kedrion SpA: Product Portfolio
Table 34: Kedrion SpA: Developments and Strategies, 2022
Table 35: LFB S.A.: Developments and Strategies, 2022
Table 36: Octapharma AG: Product Portfolio
Table 37: Octapharma AG: Developments and Strategies, 2022
Table 38: Takeda Pharmaceutical Company Limited: Product Portfolio
Table 39: Takeda Pharmaceutical Company Limited: Developments and Strategies, 2022
LIST OF FIGURES
Summary Figure: Global Market Shares of Immunoglobulins, by Region, 2021
Figure 1: Global Market Shares of Immunoglobulins, by Type, 2021
Figure 2: Global Market Shares of Immunoglobulins, by Route of Administration, 2021
Figure 3: Global Market Shares of Normal Immunoglobulins, by Application, 2021
Figure 4: Global Immunoglobulins Market, by Region
Figure 5: Global Market Shares of Immunoglobulins, by Region, 2021
Figure 6: Global Market Shares of Immunoglobulins, by Region, 2027
Figure 7: ADMA Biologics Inc.: Financials, 2020 and 2021
Figure 8: ADMA Biologics Inc.: Revenue Share, by Segment, 2021
Figure 9: ADMA Biologics Inc.: Revenue Share, by Region, 2021
Figure 10: CSL Ltd.: Annual Revenue, 2019-2021
Figure 11: CSL Ltd.: Revenue Share, by Region/Country, 2021
Figure 12: Grifols International S.A.: Financials, 2019-2021
Figure 13: Grifols International S.A.: Revenue Share, by Business Segment, 2021
Figure 14: Grifols International S.A.: Revenue Share, by Region/Country, 2021
Figure 15: Kedrion SpA: Financials, 2019-2021
Figure 16: Kedrion SpA: Revenue Share, by Segment, 2021
Figure 17: Kedrion SpA: Revenue Share, by Region, 2021
Figure 18: Octapharma AG: Financials, 2019-2021
Figure 19: Takeda Pharmaceutical Company Limited: Financials, 2020 and 2021
Figure 20: Takeda Pharmaceutical Company Limited: Revenue Share, by Region, 2021
Figure 21: Takeda Pharmaceutical Company Limited: Revenue Share, by Business Segment, 2021
Summary Figure: Global Market Shares of Immunoglobulins, by Region, 2021
Figure 1: Global Market Shares of Immunoglobulins, by Type, 2021
Figure 2: Global Market Shares of Immunoglobulins, by Route of Administration, 2021
Figure 3: Global Market Shares of Normal Immunoglobulins, by Application, 2021
Figure 4: Global Immunoglobulins Market, by Region
Figure 5: Global Market Shares of Immunoglobulins, by Region, 2021
Figure 6: Global Market Shares of Immunoglobulins, by Region, 2027
Figure 7: ADMA Biologics Inc.: Financials, 2020 and 2021
Figure 8: ADMA Biologics Inc.: Revenue Share, by Segment, 2021
Figure 9: ADMA Biologics Inc.: Revenue Share, by Region, 2021
Figure 10: CSL Ltd.: Annual Revenue, 2019-2021
Figure 11: CSL Ltd.: Revenue Share, by Region/Country, 2021
Figure 12: Grifols International S.A.: Financials, 2019-2021
Figure 13: Grifols International S.A.: Revenue Share, by Business Segment, 2021
Figure 14: Grifols International S.A.: Revenue Share, by Region/Country, 2021
Figure 15: Kedrion SpA: Financials, 2019-2021
Figure 16: Kedrion SpA: Revenue Share, by Segment, 2021
Figure 17: Kedrion SpA: Revenue Share, by Region, 2021
Figure 18: Octapharma AG: Financials, 2019-2021
Figure 19: Takeda Pharmaceutical Company Limited: Financials, 2020 and 2021
Figure 20: Takeda Pharmaceutical Company Limited: Revenue Share, by Region, 2021
Figure 21: Takeda Pharmaceutical Company Limited: Revenue Share, by Business Segment, 2021
